A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2025-05-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT05123599
- Locations
- 🇮🇹
Irccs Ospedale Maggiore Di Milano, Milano, Italy
🇳🇿New Zealand Clinical Research, Auckland, New Zealand
🇵🇱ID Clinic, Myslowice, Poland
A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 126
- Registration Number
- NCT05112939
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937)
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT05112952
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
🇩🇪APEX GmbH, Munchen, Germany
A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant
- Conditions
- Depressive Disorder, Major
- Interventions
- Other: Standard of Care (SOC)
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 7
- Registration Number
- NCT05109195
- Locations
- 🇺🇸
Brigham And Women's Hospital, Boston, Massachusetts, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇺🇸The University of Pittsburgh of the Commonwealth System of Higher Education, Pittsburgh, Pennsylvania, United States
A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem
- Conditions
- Healthy Non-dependent, Recreational Sedative UsersAbuse Potential
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 127
- Registration Number
- NCT05106153
- Locations
- 🇺🇸
Altasciences Inc., Overland Park, Kansas, United States
A Long-term Extension Study of Ustekinumab in Pediatric Participants
- Conditions
- Colitis, UlcerativeCrohn DiseaseArthritis, Psoriatic
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 151
- Registration Number
- NCT05092269
- Locations
- 🇦🇷
STAT Research S A, Buenos Aires, Argentina
🇦🇷Hospital de Ninos de Cordoba, Cordoba, Argentina
🇬🇧Royal London Hospital, London, United Kingdom
A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis
- Conditions
- HealthyArthritis, Psoriatic
- Interventions
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 11
- Registration Number
- NCT05083078
- Locations
- 🇦🇹
Medical University Graz, Graz, Austria
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 587
- Registration Number
- NCT05083169
- Locations
- 🇸🇪
Skanes universitetssjukhus, Lund, Sweden
🇸🇪Norrlands Universitetssjukhus, Umea, Sweden
🇸🇪Akademiska Sjukhuset, Uppsala, Sweden
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT05083182
- Locations
- 🇮🇹
IRCCS Ospedale Pediatrico Bambino Gesu, Roma, Italy
🇩🇰Aarhus Universitetshospital, Arhus, Denmark
🇩🇰Odense Universitets Hospital, Odense, Denmark
A Study of Lazertinib (JNJ-73841937) in Healthy Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT05076877
- Locations
- 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States